Hypertension Diagnostics Stock Price To Earning
HDIIDelisted Stock | USD 0 0.0008 38.10% |
Hypertension Diagnostics fundamentals help investors to digest information that contributes to Hypertension Diagnostics' financial success or failures. It also enables traders to predict the movement of Hypertension Pink Sheet. The fundamental analysis module provides a way to measure Hypertension Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hypertension Diagnostics pink sheet.
Hypertension |
Hypertension Diagnostics Company Price To Earning Analysis
Hypertension Diagnostics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Hypertension Diagnostics Price To Earning | (0.03) X |
Most of Hypertension Diagnostics' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hypertension Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Hypertension Diagnostics has a Price To Earning of -0.03 times. This is 100.16% lower than that of the Health Care Equipment & Supplies sector and significantly lower than that of the Health Care industry. The price to earning for all United States stocks is 100.1% higher than that of the company.
Hypertension Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hypertension Diagnostics' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hypertension Diagnostics could also be used in its relative valuation, which is a method of valuing Hypertension Diagnostics by comparing valuation metrics of similar companies.Hypertension Diagnostics is currently under evaluation in price to earning category among its peers.
Hypertension Fundamentals
Return On Asset | 3.0E-4 | ||||
Profit Margin | (0.03) % | ||||
Operating Margin | 0.0002 % | ||||
Current Valuation | 5.26 M | ||||
Shares Outstanding | 52.39 M | ||||
Price To Earning | (0.03) X | ||||
Price To Sales | 0.15 X | ||||
Revenue | 3.79 M | ||||
Gross Profit | 954.47 K | ||||
EBITDA | 72.29 K | ||||
Net Income | (125.39 K) | ||||
Cash And Equivalents | 5.66 K | ||||
Total Debt | 4.69 M | ||||
Current Ratio | 0.52 X | ||||
Book Value Per Share | (0.09) X | ||||
Cash Flow From Operations | (389.28 K) | ||||
Earnings Per Share | (0) X | ||||
Beta | -0.92 | ||||
Market Capitalization | 730.42 K | ||||
Total Asset | 1.28 M | ||||
Retained Earnings | (30.68 M) | ||||
Working Capital | (857 K) | ||||
Current Asset | 277 K | ||||
Current Liabilities | 1.13 M | ||||
Z Score | -31.6 | ||||
Net Asset | 1.28 M |
About Hypertension Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hypertension Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hypertension Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hypertension Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Hypertension Pink Sheet
If you are still planning to invest in Hypertension Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hypertension Diagnostics' history and understand the potential risks before investing.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |